Dexmedetomidine and Propofol in Children With History of Obstructive Sleep Apnea
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this research study is to examine the effects of two commonly used anesthetic drugs, dexmedetomidine and propofol, have on the shape and muscle tone of the upper airway in children, adolescents, and young adults with a history of obstructive sleep apnea (OSA) having an MRI scan.
The results of this study will help in making the best decisions regarding the anesthesia medications that are most appropriate for children, adolescents, and young adults with OSA during MRI studies.
| Condition | Intervention | Phase |
|---|---|---|
|
Sleep Apnea, Obstructive |
Drug: Dexmedetomidine Drug: Propofol |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Effect of Increasing Depth of Dexmedetomidine and Propofol Anesthesia on Upper Airway Morphology in Children With History of Obstructive Sleep Apnea |
- Cross sectional area of the pharyngeal airway [ Time Frame: during MRI within first 10 minutes of scanning ] [ Designated as safety issue: No ]The primary outcome measures will be the cross sectional area of the pharyngeal airway of the patients measured at two levels (soft palate and base of the tongue).
- Patient obstructive index and airway maintenance until Recovery Room discharge [ Time Frame: during MRI and until Recovery Room discharge - approximately 30 - 250 minutes ] [ Designated as safety issue: No ](a) anteroposterior dimension and transverse dimension of the pharyngeal airway of the patients measured at two levels: soft palate and base of the tongue, (b) patient movement during scan,(c) episodes of low oxygen saturation(d) placement of adjunct airway such as oral/nasal airway, laryngeal mask airway or endotracheal tube, (e) examine the relationship between OSA severity and episodes of desaturation and artificial airway placement, (f) PACU discharge time (g) arterial blood pressure and heart rate relative to baseline following dexmedetomidine and propofol.
| Estimated Enrollment: | 60 |
| Study Start Date: | June 2009 |
| Estimated Study Completion Date: | February 2012 |
| Estimated Primary Completion Date: | November 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Propofol |
Drug: Propofol
Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of propofol 2 mg/kg will be administered over 2 minutes followed by a continuous infusion of propofol at rate of 100 mcg/kg/minute using a syringe pump.
Other Name: Diprivan
|
| Active Comparator: Dexmedetomidine |
Drug: Dexmedetomidine
Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of dexmedetomidine 1 mcg/kg will be administered over 10 minutes followed by a continuous infusion of dexmedetomidine at rate of 1 mcg/kg/h using a syringe pump.
Other Name: Precedex
|
Detailed Description:
Patients with OSA are at risk for airway obstruction (a condition that makes it difficult to breath) during sedation and anesthesia. Dexmedetomidine and propofol are safe and effective drugs regularly used by anesthesiologists. These drugs are used to put patients to sleep for operations and certain studies like MRI scans. However, there have been no studies describing the effects these drugs have on the upper airway of children, adolescents, and young adults with OSA.
Eligibility| Ages Eligible for Study: | 12 Months to 25 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with documented history of OSA by polysomnography who require anesthesia for MRI sleep study or MRI brain imaging study.
- Subjects must be 12 months to 25 years of age (inclusive)
- Either the subject (if subject's age is 18-25) or the subject's legally authorized representative has given written informed consent to participate in the study
Exclusion Criteria:
- The subject has life-threatening medical conditions (American Society of Anesthesiologists Physical Status 4, 5 or 6). The American Society of Anesthesiologists (ASA) classification scale is a measure of physical status or how healthy the patient is. For our study, we will focus on children which are defined as ASA I, II or III which means a healthy child (ASA I), a child with a systemic disease that is mild and well controlled (ASA II) or a child with systemic disease that is severe and controlled (ASA III).
- The subject is allergic to or has a contraindication to propofol or dexmedetomidine.
- The subject has a tracheostomy or other mechanical airway device
- The subject is not scheduled to receive anesthesia-sedation care for the MRI
- The subject has a history or a family (parent or sibling) history of malignant hyperthermia.
Contacts and Locations| Contact: Mohamed Mahmoud, MD | 513636 4408 | mohamed.mahmoud@cchmc.org |
| United States, Ohio | |
| Cincinnati Children's Hospital Medical Center | Recruiting |
| Cincinnati, Ohio, United States, 45229 | |
| Contact: Mohamed Mahmoud, MD 513-636-4408 mohamed.mahmoud@cchmc.org | |
| Principal Investigator: Mohamed Mahmoud, MD | |
| Principal Investigator: | Mohamed Mahmoud, MD | Children's Hospital Medical Center, Cincinnati |
More Information
Publications:
| Responsible Party: | Mohamed Mahmoud, Cincinnati Children's Hospital Medical Center |
| ClinicalTrials.gov Identifier: | NCT01344759 History of Changes |
| Other Study ID Numbers: | CCHMC 2009-0514 |
| Study First Received: | April 21, 2011 |
| Last Updated: | April 28, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Children's Hospital Medical Center, Cincinnati:
|
Obstructive Sleep Apnea MRI Pediatrics |
Dexmedetomidine Propofol Anesthesia |
Additional relevant MeSH terms:
|
Apnea Sleep Apnea Syndromes Sleep Apnea, Obstructive Respiration Disorders Respiratory Tract Diseases Signs and Symptoms, Respiratory Signs and Symptoms Sleep Disorders, Intrinsic Dyssomnias Sleep Disorders Nervous System Diseases Propofol Dexmedetomidine Anesthetics, Intravenous Anesthetics, General |
Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Hypnotics and Sedatives Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents |
ClinicalTrials.gov processed this record on June 17, 2013